Authors are requested to submit the manuscripts only through IJAM web portal, submission directly to journal mail ids will not be considered.
IJAM is now a member of Crossref. Articles published from the year 2017 onwards are assigned to DOI. • Articles are invited for the first issue of the year 2022.
Dr. S. Yavanarani1* and Dr. R. Selvakumar2
1.Yavanarani Siddha Clinic, Pillaiyarpalayam,Kanchipuram,Tamilnadu, India,631501.
2.Siddha Government Hospital,Tiruttani,Tiruvallur, Tamilnadu,India-631209
Ind.J.Applied.Microbiol. 2022 .24(1) : 32-39
Background: There are many health hazards associated with diabetes mellitus, characterized byhigh blood glucose levels caused by defects in insulin secretion or insulin action, or both. Amongthe most life-threatening diseases, cancer presents many health hazards both in developed anddeveloping countries, characterized by irregular cell proliferation. The prevalence of diabetes andcancer are escalating day by day and this shows the urgently require for the management ofdiabetes and cancer. Methods: In this study was aimed to evaluate the antidiabetic and anticancerpotential of Siddha polyherbal formulation Tulasi oil (SPFTO) by glycosylation of hemoglobinassay, glucose uptake by yeast cells, alpha amylase inhibition and MTT assay method,respectively. Results: The inhibition rate in all concentrations of Tulasi oil exhibited higherinhibition of glycosylation, glucose uptake in yeast cells assay and ? amylase as compared withthe standard drug. The cytotoxic activity for MCF7 cell line was 65.75% at 50 ?g/mLconcentration by MTT assay method. Conclusion: The results of this study demonstrate that theSiddha polyherbal formulation Tulasi oil has significant antidiabetic and antiproliferativeactivities.
Keywords: Siddha, Tulasi oil, antidiabetic, antiproliferative, MCF7 cell line
Download this article as